Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Pietro

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Journal of Translational Medicine|April 18, 2015
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort studyElena Raffetti, Francesco Donato, Filippo Castelnuovo, et al.
The Journal of Infection|December 13, 2016
Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C - Clonal complex 11 in the Florence province, Italy, 2015-2016Francesco Maria Fusco, Filippo Baragli, Barbara Del Pin, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort studyEugenia Quiros-Roldan, Elena Raffetti, Francesco Castelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 14, 2015
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter StudyElena Raffetti, Francesco Donato, Chiara Pezzoli, et al.
BMC Public Health|August 26, 2016
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER CohortElena Raffetti, Maria Concetta Postorino, Francesco Castelli, et al.
BMC Infectious Diseases|March 17, 2017
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohortMaria Concetta Postorino, Mattia Prosperi, Emanuele Focà, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 20, 2007
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis)Stefano Rusconi, Nicola Gianotti, Fulvio Adorni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2015
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected PatientsGiuseppe Lapadula, Silvia Costarelli, Liliane Chatenoud, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Journal of Translational Medicine|April 18, 2015
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort studyElena Raffetti, Francesco Donato, Filippo Castelnuovo, et al.
The Journal of Infection|December 13, 2016
Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C - Clonal complex 11 in the Florence province, Italy, 2015-2016Francesco Maria Fusco, Filippo Baragli, Barbara Del Pin, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort studyEugenia Quiros-Roldan, Elena Raffetti, Francesco Castelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 14, 2015
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter StudyElena Raffetti, Francesco Donato, Chiara Pezzoli, et al.
BMC Public Health|August 26, 2016
The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER CohortElena Raffetti, Maria Concetta Postorino, Francesco Castelli, et al.
BMC Infectious Diseases|March 17, 2017
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohortMaria Concetta Postorino, Mattia Prosperi, Emanuele Focà, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 20, 2007
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis)Stefano Rusconi, Nicola Gianotti, Fulvio Adorni, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2015
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected PatientsGiuseppe Lapadula, Silvia Costarelli, Liliane Chatenoud, et al.
Pageof 6